Johnson & Johnson Innovation

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.

Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

Certa Dose, Inc. designs and develops syringes for eliminating pediatric medication dosing errors. It offers color coded syringes to determine the medicine doses for pediatrics. The company’s syringes are used by parents, nurses, doctors, and paramedics at various points of care, including pre-hospitals, hospitals, and homes. Certa Dose, Inc. was founded in 2013 and is based in Denver, Colorado with operations in Indianapolis, Indiana.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Carbon brings together innovations in software, hardware, and molecular science to deliver industry-leading digital manufacturing solutions. With proprietary Carbon Digital Light Synthesis (DLS) technology and family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and speeding time to market. Carbon was founded by Dr. Joseph DeSimone and Philip DeSimone in 2013.

The SuperX team is engaged in the discovery of antibodies against an undisclosed target in the blood coagulation cascade. SuperX hopes to reach the clinic in 2019.A preclinical stage biopharmaceutical company, based at Babraham Research Campus, developing novel anticoagulant drugs

Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Dermala is a biotech company focuses on human microbiome, data analytics, and behavior science to develop treatments for skin diseases.

Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.

Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

RefleXion Medical Inc., a medical equipment company, develops a biologically-guided radiotherapy system (BgRT) for cancer treatment. Its technology allows tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. The company’s technology also enables simultaneous treatment of tumors throughout the body, as well as real-time dose adaptation to specific biological characteristics of the tumor. RefleXion Medical Inc. has a strategic collaboration agreement with Telix Pharmaceuticals Limited; and a strategic partnership with HealthMyne Inc. The company was incorporated in 2009 and is based in Hayward, California.

XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.

Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.

Carbon brings together innovations in software, hardware, and molecular science to deliver industry-leading digital manufacturing solutions. With proprietary Carbon Digital Light Synthesis (DLS) technology and family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and speeding time to market. Carbon was founded by Dr. Joseph DeSimone and Philip DeSimone in 2013.

MedCrypt is a medical device company that provides data security as a service to medical device OEMs. From medical imaging device to implantable devices like pacemakers, MedCrypt ensures that devices act only on instructions from trusted sources. It brings security features to medical devices, from pacemakers to surgical robots, in a few lines of code. The company enables engineers to implement these security features properly as quickly as possible, allowing them to get back to designing life-changing clinical features. MedCrypt was founded in 2016 and is headquartered in Encinitas, California, United States.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.

AmacaThera Inc., biotechnology company, engages in developing and commercializing injectable hydrogel platform technology for medical applications. The company was founded in 2016 and is based in Toronto, Canada.

Viora Health provides technology to improve patient access to care and experience for programs that reduce disease progression in order to improve outcomes and reduce episodic costs.

Glyscend, Inc. develops therapeutic for the treatment of metabolic diseases. The company provides a non-invasive intestinal coating for the treatment of type 2 diabetes. Glyscend, Inc. was incorporated in 2014 and is based in Baltimore, Maryland.

Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

WellDoc is developing the next generation of technology solutions to support chronic disease management. Its mission is to improve the lives of people with chronic diseases they fulfill their mission by integrating clinical, behavioral, and motivational applications with everyday technologies, like the internet and cell phone, to engage patients and healthcare providers in ways that dramatically improve outcomes and significantly reduce healthcare costs. It was founded in 2005 and headquartered in Columbia, Maryland.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Asceneuron SA is a biotechnology company that discovers and develops therapeutics for neurodegenerative disorders with unmet medical needs. It offers therapeutics for the treatment of progressive supranuclear palsy, orphan tauopathies, and Alzheimer’s and Parkinson’s diseases. The company was founded in 2012 and is based in Lausanne, Switzerland. Asceneuron SA operates as a subsidiary of Merck KGaA.

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

V-Wave Ltd. develops percutaneous implantable therapeutic devices for chronic heart failure patients. It offers V-Wave Shunt, a biocompatible inter-atrial unidirectional implant that is used to treat chronic heart failure patients with preserved and reduced ejection fraction (diastolic and systolic heart failure). The company was founded in 2009 and is based in Caesarea, Israel with additional offices in Israel and the United States.

Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.

Joint Purification Systems, Inc. is a privately held company located in Solana Beach, CA. Founded in 2013, JPS is dedicated to providing novel drug and device combination products for treating musculoskeletal infection.

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC093, a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding cleaved collagen in the extracellular matrix of solid tumors; TRC105, a human chimeric monoclonal antibody that binds endoglin for angiogenesis; TRC102, a molecule that reverses resistance to chemotherapeutics; and TRC101, a nanoliposome embedded with ceramide used to improve the activity and delivery of chemotherapeutics. TRACON Pharmaceuticals, Inc. was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in April 2005. The company was founded in 2005 and is based in San Diego, California.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

V-Wave Ltd. develops percutaneous implantable therapeutic devices for chronic heart failure patients. It offers V-Wave Shunt, a biocompatible inter-atrial unidirectional implant that is used to treat chronic heart failure patients with preserved and reduced ejection fraction (diastolic and systolic heart failure). The company was founded in 2009 and is based in Caesarea, Israel with additional offices in Israel and the United States.

XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Petra Pharma Corporation, a pharmaceutical company, discovers and develops therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. It focuses on novel enzyme targets that play a central role in various important cellular processes, including cell division, growth, trafficking, and signaling. The company was incorporated in 2015 and is based in New York, New York.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn’s disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

DJS Antibodies is discovering game-changing medicines to address recognised unmet medical need. Discovering new medicines is extremely difficult and most traditional methods fail. They have a breakthrough technology which overcomes this hurdle – revolutionising drug development. Early work, funded by Johnson&Johnson, has shown an unprecedented success rate in discovering lead antibodies and has lead to the development of lead programmes in both cancer and kidney disease.

XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.

EpigenCare is connecting consumers with skincare companies through a direct-to-consumer skincare test and web platform on the Ethereum network. Consumers receive actionable recommendations of optimized skincare products to use, as well as assess the progress of their skincare routines, based on their skin's epigenetic profiles. The recommendation engine looks at the functional state of a panel of epigenetic markers strongly correlated with skin quality indicators (e.g., aging, moisture retention, elasticity, etc.), and how skincare product ingredients affect them. It offers SKINTELLI, a direct-to-consumer personal epigenomics test that measures DNA methylation levels of a proprietary panel of genes responsible for key skin quality factors (e.g., aging, elasticity, moisture retention, etc.). The SKINTELLI web platform empowers you with the knowledge of which products truly work for your skin. EpigenCare was founded in 2017 and based in Farmingdale, New York.

E-Scape Bio, Inc., a biopharmaceutical company, discovers and develops small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. Its programs improve the lives of patients suffering from Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Nucleome Therapeutics is a biotechnology company transforming drug discovery using the 3D structure of the genome. The pioneering genomics platform uses the 3D structure of the genome and ML-powered computational genomics to decode and mine the regulatory “dark matter” of the human genome to help deliver the next generation of genetically guided therapeutics. They harnessing the nucleome to unlock the non-coding genome for human health. Nucleome Therapeutics was founded in 2019 and is headquartered in Headington, Oxford, United Kingdom.

Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.

Manus Neurodynamica Ltd manufactures medical diagnostic technologies for neuromotor impairments, including the non-invasive diagnosis and monitoring of Parkinson’s disease. Its technologies are used in academic research, pharmaceutical research, and non-medical applications. The company was founded in 2008 and is based in North Shields, United Kingdom.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest digital blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data. Our proprietary technology can detect novel signature sequences, biomarkers, and polygenic risk scores by integrating “multi-omics” data, electronic healthcare record (EHR) data, and textual information such as scientific manuscripts.

Cara by HiDoc Technologies is an pharmaceutical company that empowers patients suffering from chronic digestive diseases. At Cara Care they develop companion digital therapeutics to enhance state of the art therapies for GI diseases. Founded in 2015, Cara is based in Berlin, Berlin, Germany.

Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.

Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.